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Background: The purpose of this study was to develop calcium phosphate nanocomposite 
particles encapsulating plasmid DNA (CP-pDNA) nanoparticles as a nonviral vector for gene 
delivery.
Methods: CP-pDNA nanoparticles employing plasmid transforming growth factor beta 1 
(TGF-β1) were prepared and characterized. The transfection efficiency and cell viability of 
the CP-pDNA nanoparticles were evaluated in mesenchymal stem cells, which were identified 
by immunofluorescence staining. Cytotoxicity of plasmid TGF-β1 and calcium phosphate to 
mesenchymal stem cells were evaluated by MTT assay.
Results: The integrity of TGF-β1 encapsulated in the CP-pDNA nanoparticles was maintained. 
The well dispersed CP-pDNA nanoparticles exhibited an ultralow particle size (20–50 nm) 
and significantly lower cytotoxicity than Lipofectamine™ 2000. Immunofluorescence staining 
revealed that the cultured cells in this study were probably mesenchymal stem cells. The cel-
lular uptake and transfection efficiency of the CP-pDNA nanoparticles into the mesenchymal 
stem cells were higher than that of needle-like calcium phosphate nanoparticles and a standard 
calcium phosphate transfection kit. Furthermore, live cell imaging and confocal laser microscopy 
vividly showed the transportation process of the CP-pDNA nanoparticles in mesenchymal stem 
cells. The results of a cytotoxicity assay found that both plasmid TGF-β1 and calcium phosphate 
were not toxic to mesenchymal stem cells.
Conclusion: CP-pDNA nanoparticles can be developed into an effective alternative as a non-
viral gene delivery system that is highly efficient and has low cytotoxicity.
Keywords: calcium phosphate nanoparticles, transfection, gene delivery, cellular uptake, 
mesenchymal stem cells
Introduction
Gene therapy, ie, delivery of therapeutic nucleic acids to target cells to replace a   missing 
or defective gene, has emerged as an alternative treatment of acquired or inherited genetic 
disorders currently considered incurable, such as cancer,1,2 diabetes,3 and hemophilia.4 
Because naked DNA can scarcely penetrate most cell membranes before being degraded 
by nucleases, effective gene carriers or vectors that do not cause vector-associated 
toxicity are highly desirable.5 To achieve this objective, both viral and nonviral gene 
vectors have been widely investigated. Among these   carriers, viral vectors6 appear to be 
the most effective because of the natural tendency of viruses to infect cells.   However, 
these viral vectors have significant shortcomings, such as an immune response against 
the transfection system, cancer induction, poor target specificity, and a low capac-
ity to incorporate exogenous genes,7,8 that limit their application in gene therapy. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Therefore, it is highly desirable to design and fabricate a safe 
and   effective nonviral gene delivery vector. Nonviral gene 
vehicles have been undergoing intensive research due to sev-
eral advantages over viral carriers, such as biocompatibility 
and biodegradability, a lack of immunogenicity, negligible 
toxicity, the   ability to carry large therapeutic genes, and a 
reduced production cost.9 Currently, the most commonly 
used nonviral vectors are complexes composed of plasmid 
DNA and cationic lipids or cationic polymers. Nevertheless, 
cationic lipids and cationic polymers are accompanied by a 
number of drawbacks, such as their relatively large size and 
toxicity both in vitro and in vivo.10
In consideration of the stumbling blocks existing for 
both cationic lipids and cationic polymers, inorganic nano-
particles, such as metal and metal oxide nanoparticles,11–13 
carbon nanotubes,14 and calcium phosphate nanoparticles,15 
have emerged as alternatives due to their versatile properties 
suitable for cellular delivery, which include wide availability, 
rich functionality, biocompatibility, the potential capacity 
of target delivery, and the controlled release of the carried 
DNA. As one of the most commonly used inorganic materi-
als in biochemistry and biotechnology, calcium phosphate 
nanoparticles enjoy several inherent properties that set this 
system apart for gene delivery. Unlike metal and metal oxide 
nanoparticles which are difficult to prepare,13 and carbon 
nanotubes which are limited by safety issues in biomedical 
applications,16 calcium phosphate has excellent biocompati-
bility because it can be found throughout the body in the form 
of amorphous calcium phosphate and crystalline hydroxyapa-
tite, which is the major component of bone and tooth enamel. 
Additionally, reasonably high but benign concentrations of 
Ca2+ and PO4
3− (1–5 mM) occur in all vertebrates and are 
naturally nontoxic as well as bioresorbable.17 Moreover, the 
solubility of calcium phosphate is variable, as regulated by 
the kidney.18 This natural occurrence of calcium phosphate 
is one of its primary advantages over other synthetic gene 
delivery systems.
In the last decade, calcium phosphate-DNA nanoparticles 
have been widely investigated to transfect different kinds 
of cell lines. Several developments have been reported 
regarding calcium phosphate particles encapsulating 
therapeutic nucleic acid and transfecting it into liver cells,19 
fibroblasts,20 osteoblasts,21 tumor cells22 and other cells. 
In one case, Roy et al23 prepared ultralow size (80 nm) 
calcium phosphate-DNA nanoparticles with a modified 
p-amino-1-thio-β-galactopyranoside ligand, and these 
calcium   phosphate-DNA nanoparticles were then used as 
nonviral vectors for β-galactopyranoside receptor-targeted 
gene delivery. Bisht et al24 synthesized nanoparticles of 
calcium phosphate encapsulating plasmid DNA which were 
used to transfect HeLa cell lines, and the results displayed 
higher transfection efficiency than that of the commercial 
transfecting reagent, Polyfect™. They also reported that 
calcium phosphate nanoparticles can be carried across the cell 
membrane via calcium ion channel-mediated endocytosis. In 
another study reported by Liu et al,25 when calcium phosphate 
nanoparticles combined with suicide genes yCDglyTK for 
nasopharyngeal carcinoma therapy in vitro, just 24.76% of 
cells survived when the wild-type CNE-2 cells were treated 
with the calcium phosphate nanoparticle-yCDglyTK com-
plex plus the prodrug, 5-FC (200 mg/mL), indicating that 
calcium phosphate nanoparticles might be a potential vector 
for gene therapy. More recently, more and more attention 
has been focused on calcium phosphate nanoparticles for 
gene delivery, resulting in wider and deeper application of 
calcium phosphate in the field of gene therapy. Zhang et al26 
synthesized PEGylated calcium phosphate nanocomposites 
which were used as smart environment-sensitive carriers 
for siRNA delivery. Furthermore, calcium phosphate-DNA 
nanoparticles could also be employed together with alginate 
hydrogels to induce in vivo osteogenesis, as reported by 
Krebs et al.27
The technique of calcium phosphate coprecipitation for 
in vitro transfection is used as a routine laboratory procedure 
and relies heavily on divalent metal cations, such as Ca2+, 
Mg2+, Mn2+, and Ba2+, forming ionic complexes with the 
helical phosphates of DNA.23 Therefore, calcium phosphate 
forms complexes with the nucleic acid backbone. Tradition-
ally, amorphous calcium phosphate particles can be formed 
in a relatively straightforward precipitation reaction. For 
instance, mixing a calcium chloride solution containing 
DNA and a phosphate-buffered saline solution results in 
precipitates consisting of calcium phosphate and DNA.28 
However, the calcium phosphate nanoparticles prepared by 
these schemes are relatively large (greater than 100 nm) and 
have significant agglomeration.29 These shortcomings have 
severely handicapped the process of cellular uptake after 
transfection, leading to decreased transfection efficiency.
Taking these problems into consideration, many research-
ers have been attempted to prepare ultralow-sized calcium 
phosphate nanoparticles entrapping DNA molecules. 
Liu et al25 reported a scheme to prepare calcium phosphate 
nanoparticles ranging from 24 to 35 nm in size and coated 
with bovine serum albumin as an efficient gene carrier in 
cancer gene therapy. Pedraza et al30 have conducted a series 
of comprehensive investigations on the physicochemical International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  characteristics of calcium phosphate nanoparticles, which 
are the factors affecting transfection efficiency, and found 
that the key parameters for effective calcium phosphate 
nanoparticle transfection were an optimal concentration of 
calcium and chloride ions and a nanosized nonagglomerated 
precipitate. Recently, several researchers29,31,32 encapsulated 
organic dyes into calcium phosphate nanocomposite particles 
for intracellular imaging and drug delivery to cells. In these 
studies, researchers developed a new strategy to produce 
ultralow sized and well dispersed calcium phosphate nano-
composite particles.
Enlightened by these previous studies, we herein con-
structed calcium phosphate nanoparticles incorporating 
plasmid transforming growth factor beta 1 (TGF-β1), which 
are ultrasmall and show excellent dispersion in medium. 
These plasmid-loaded calcium phosphate nanoparticles were 
subsequently used to transfect mesenchymal stem cells from 
rat femur marrow. To the best of our knowledge, although 
calcium phosphate nanoparticles have been employed to 
transfect many kinds of cells, their application as a gene 
vector for direct mesenchymal stem cell transfection has 
rarely been reported. Mesenchymal stem cells are a promis-
ing alternative for use in gene therapy due to their strong 
capabilities of self-renewal and differentiation into various 
types of cells.33 The functional cytokine TGF-β1 encoded by 
the plasmid was introduced in the current study due to its 
favorable properties in gene therapy.34
Materials and methods
Materials
The nonionic surfactant poly (oxyethylene)-nonylphenyl 
ether (Igepal CO-520) cyclohexane and silane-coupling 
agent 3-aminopropyltriethoxysilane (APS) were purchased 
from Sigma-Aldrich (St Louis, MO). Glacial acetic acid 
and absolute ethanol were obtained from Chemical Reagent 
Co, Ltd, of China National Pharmaceutical Group and 
were used without further purification. All of the aqueous 
stock solutions were prepared with deionized water. Silica 
spheres (50 µm in size, 60 Å in pore size) were purchased 
from Sepax Technologies (Newark, DE). Fetal bovine 
serum, Dulbecco’s modified Eagle’s medium (DMEM), 
penicillin, streptomycin, and trypsin were obtained from 
Gibco-  Invitrogen (Grand Island, NY). The standard calcium 
phosphate transfection kit and other chemicals were obtained 
from Beyotime Biotechnology (Jiangsu, China), except when 
otherwise specified.
Rabbit antimouse CD13, CD44, CD106 antibodies, sheep 
antirabbit IgG labeled with Cy3, and   vimentin antibody 
were purchased from Boston Corporation (Wuhan, China). 
TGF-β1 plasmid (Figure 1A) was kindly provided by 
Dr Guang-Jian Zhang at the Medical College of Wisconsin 
(Milwaukee, WI). Purified TGF-β1 plasmid was prepared 
with the Pure Yield Plasmid Midiprep Kit (Promega, 
  Madison, WI). Propidium iodide and colchicine were sup-
plied by the Beyotime Institute of Biotechnology (Shanghai, 
China). One-day-old male white Sprague-Dawley rats were 
supplied by the Experimental Animal Center of Jiangsu 
  University. The animal experimental protocol was approved 
by the University Ethics Committee for the use of experi-
mental animals and conformed to the Guide for Care and 
Use of Laboratory Animals.
Preparation of CP-pDNA nanoparticles 
in microemulsion
The preparation process for plasmid DNA-loaded calcium 
phosphate (CP-pDNA) nanoparticles followed a published 
report29 with some modifications. Briefly, two separate 
microemulsions (A and B) were formed with a cyclohexane/
Igepal CO-520/water system in which the cyclohexane 
acted as the oil phase reaction medium and Igepal CO-520 
was the   surfactant. In the first step, a 29% (v/v ratio) Igepal 
CO-520 solution in cyclohexane was prepared. Excessive 
water was then added to bring the total volume of water 
to 450 µL to adjust the molar ratio of water to Igepal 
CO-520 to 10. The results of previous trial tests showed that 
because both microemulsion A and B were of the water-in-oil 
type, when the molar ratio was over 10, the emulsion would 
be destroyed, and when the molar ratio was less than 10, 
there was excess surfactant (data not shown). Thus, the 
optimal molar ratio of water to Igepal CO-520 is 10. For the 
microemulsion A preparation, 2.94 µg of plasmid DNA in 
70 µL of 1.36 mM calcium chloride was added to 25 mL of 
the above-mentioned Igepal CO-520 solution in cyclohexane. 
The mixture was stirred continuously for 2 minutes to form 
microemulsion A. Similarly, for microemulsion B, 2.94 µg 
of plasmid DNA in 70 µL of 0.35 mM disodium hydrogen 
phosphate and 50 µL of 0.2 M Tris-HCl buffer (pH 7.4) were 
added to 25 mL of Igepal CO-520 solution in   cyclohexane. 
The mixture was stirred continuously for 2 minutes to 
form microemulsion B. The amount of plasmid DNA 
was determined according to the loading capacity results 
described below. The addition of the aqueous solution to the 
  cyclohexane/Igepal CO-520 solution forms a self-assembled, 
reverse microemulsion suspension. Both of the microemul-
sions were optically clear solutions. Microemulsion B was 
added into microemulsion A at 20 drops per minute with International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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continuous magnetic stirring at 4°C. The resulting micro-
emulsion was allowed to undergo emulsion exchange for 
another 10 minutes with continuous stirring until complete 
translucency, during which time the doped calcium phosphate 
nanoparticles precipitated in the emulsions. Without adding 
dispersant, the CP-pDNA nanoparticle microemulsion was 
diluted by pH-adjusted absolute ethanol (pH 7.0) before 
van der Waals chromatography laundering.
Isolation of CP-pDNA nanoparticles
CP-pDNA nanoparticle isolation was performed using the 
van der Waals chromatography laundering method, modi-
fied from a published report.29 Prior to the column prepara-
tion, silica spheres (50 µm, 60 Å) were pretreated with the 
  following steps: silica microspheres (90 g) were mixed with 
APS (0.336 mL), glacial acetic acid (1.5 mL), double-distilled 
water (7.5 mL), and absolute ethanol (150 mL). The spheres 
were stirred overnight and subsequently oven-dried at 70°C. 
The CP-pDNA nanoparticle microemulsion (50 mL) was 
diluted by absolute ethanol (pH 7.0, 150 mL) before loading 
onto the silica column. The silica column was prepared by 
packing APS-treated silica microspheres into an empty HR 
5/5 column (Piscataway, NJ) and equilibrating with absolute 
ethanol before sample loading. The high-pressure liquid chro-
matography (HPLC) system used to isolate the CP-pDNA 
nanoparticles was the Waters HPLC system (Waters 510 
HPLC Pump, WatersTM 486 tunable absorbance detector). 
The terminal end of the column was connected to a Waters 
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Figure 1 (A) structure map of plasmid TgF-β1. (B) Ultraviolet high-pressure liquid chromatography analysis of CP-pDNA nanoparticles samples eluted with ethanol/water 
(70:30, v/v) solvent from the silica column. The samples were collected at 4, 8, 10, and 12 hours after elution started. Chromatography was detected at 260 nm. (C) Agarose 
gel electrophoresis of CP-pDNA nanoparticles. Panel a shows the plasmid DNA loading capacities of the CP-pDNA nanoparticles. DNA was detected with ethidium bromide 
in the gel. Free plasmid and CP-pDNA nanoparticles made with calcium phosphate/plasmid DNA ratios equal to 0.1:1, 0.5:1, 1:1, 2:1, 5:1, and 10:1 (from left side to right side) 
were tested. Panel b shows an assay of plasmid DNA integrity in the CP-pDNA nanoparticles. The plasmid DNA released from the CP-pDNA nanoparticles was digested 
with smaI and evaluated on agarose gel. Lane 1 shows plasmid DNA recovered from the CP-pDNA nanoparticles digested with smaI; lane 2 shows free plasmid DNA 
digested with smaI; lane 3 shows free plasmid DNA; lane 4 shows the DNA marker. Panel c shows an assay of the topological structure of plasmid DNA released from the 
CP-pDNA nanoparticles.
Abbreviations: TgF-β1, transforming growth factor beta-1; CP, calcium phosphate; pDNA, plasmid DNA; sma I, Serratia marcescens I; UV, ultraviolet.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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486 ultraviolet-visible spectrometer with a detector set at 
the wavelength of 260 nm. The suspension of CP-pDNA 
nanoparticles was pumped into the HPLC system followed 
by absolute ethanol as the washing solvent. The CP-pDNA 
nanoparticles were attracted to the stationary phase (the 
silica spheres) by van der Waals forces in the low dielectric 
media (absolute ethanol). The column was first washed with 
absolute ethanol (400 mL) to minimize the surfactant Igepal 
CO-520 concentration (less than 1 × 10−3 M) with the entire 
HPLC operation fixed at 0.5 mL/minute. During this process, 
the free plasmid DNA and the cyclohexane were completely 
removed (below the detection limits of the ultraviolet HPLC 
analysis). After ethanol washing, the nanoparticles, which 
remained on the column due to van der Waals attractive 
forces, were eluted with a 70:30 ethanol-water solution 
with NaCl (5 × 10−4 M, prepared with CO2-free deionized 
water, pH 7) at a speed of 0.5 mL/minute for 12 hours. 
The eluted CP-pDNA nanoparticles in the 70:30 ethanol-
water with NaCl (5 × 10−4 M) solution were concentrated 
by whirl-evaporation for 6 hours at 37°C and subsequently 
dialyzed with phosphate-buffered saline overnight at 4°C 
using a dialysis bag (with a cutoff molecular weight of 
12 kDa, Biosharp, USA provided by Nanjing Super-bio 
Biotechnology Co, Ltd, Nanjing, China) to remove the NaCl. 
The final CP-pDNA nanoparticle solution within the dialysis 
bag was collected and stored at 4°C until use.
Determination of loading capacity, 
integrity, and topological structure
To determine the optimized plasmid DNA loading capac-
ity of calcium phosphate nanoparticles, different amounts 
of TGF-β1 DNA (from 0.1 to 10 µg) were used to prepare 
CP-pDNA nanoparticle microemulsions, while the same 
amounts of calcium and phosphate ions (1 µg) were used for 
different preparations. The isolated CP-pDNA nanoparticle 
samples were dispersed in water and subsequently subjected 
to agarose gel electrophoresis. For each sample, 10 µL of 
nanoparticles were loaded onto a 1% agarose gel containing 
propidium iodide and electrophoresed at 100 V for one hour. 
If the calcium phosphate nanoparticles were oversaturated 
with plasmid DNA, the free plasmid DNA could be observed 
in the agarose gel. The CP-pDNA nanoparticles were centri-
fuged at 50,000 rpm for 15 minutes at 4°C. The pellet was 
dissolved in sodium acetate (pH 3.0). The TGF-β1 plasmid 
DNA could be released from the CP-pDNA nanoparticles 
because the calcium phosphate was sensitive to the mildly 
acidic conditions. The plasmid DNA was concentrated and 
subsequently subjected to SmaI digestion and agarose gel 
electrophoresis. The integrity of the plasmid DNA was 
  analyzed based on the results of the gel electrophoresis. 
  Additionally, the topological structure of free plasmid DNA 
as well as plasmid DNA released from CP-pDNA nano-
particles with different weight ratios of calcium phosphate 
to plasmid DNA (0.5:1, 1:1, 2:1, 5:1, and 10:1) were also 
investigated via gel electrophoresis.
Transmission electron microscopy
Transmission electron microscopy (TEM) images were 
captured on a JEM-2100 instrument (JEOL, Tokyo, Japan). 
Briefly, one drop of the freshly prepared nanoparticle suspen-
sion was placed onto a carbon film grid with a copper backing 
and was self-dried at room temperature (25°C). The dried grid 
was then examined under the electron microscope.
Isolation and identification of mesenchymal 
stem cells
Bone marrow cells were harvested by flushing the tibia 
and femur of one-day-old male white Sprague-Dawley rats 
with DMEM supplemented with 10% fetal bovine serum. 
  Nucleated cells were isolated from bone marrow cells 
with a density gradient Ficoll solution (GE Healthcare, 
  Braunschweig, Germany) and subsequently resuspended 
in complete culture medium supplemented with penicil-
lin 50 U/mL and streptomycin 50 mg/mL. The nucleated 
cells were incubated at 37°C in 5% humidified CO2 for 
12–14 days as the primary culture or until the formation of 
large colonies.
When large colonies developed to 80%–90% confluence, 
passage 3 cells were washed three times with phosphate-buff-
ered saline and trypsinized with 0.25% trypsin in 1 mM EDTA 
for 5 minutes at 37°C. After centrifugation, the mesenchymal 
stem cells were resuspended in fetal bovine serum-supple-
mented medium and seeded in 24-well plates (Corning, NY) 
at a density of 5 × 104 cells per well (a   density of 30,000 cells/
well) and were expanded to 80%–90%   confluence (approxi-
mately 100,000 cells) before immunofluorescence staining. 
Briefly, the cells in each well were washed three times with 
500 µL of phosphate-buffered saline and subsequently fixed 
in 500 µL of 4% paraformaldehyde for 4 hours. The primary 
antibodies CD13, CD44, CD106, CD34, CD71, and vimentin 
were diluted with phosphate-buffered saline at an antibody/
phosphate-buffered saline ratio of 1:100 (v/v) according to 
the manufacturer’s instructions and were added into each 
well (300 µL/well) followed by an overnight incubation at 
4°C. After incubation, the cells were washed three times with 
500 µL of phosphate-buffered saline followed by the addition International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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of sheep-antirabbit IgG secondary antibody labeled with CY3 
(300 µL/well) for one hour of incubation at room temperature. 
After washing with 500 µL of phosphate-buffered saline as 
described above, 300 µL of 5 µg/mL Hoechst 33342 was 
added to each well and incubated for 10 minutes at room 
temperature. Finally, the cells were washed with 500 µL of 
phosphate-buffered saline as described above and observed 
on a fluorescent microscope. After transfection, immunofluo-
rescence staining was also conducted as described above to 
check if the stem cells had differentiated.
Transfection of mesenchymal stem cells 
with CP-pDNA nanoparticles
The mesenchymal stem cells were seeded 24 hours prior 
to the CP-pDNA nanoparticles transfection at a density 
of 2 × 105 cells per well on a 24-well plate. In each well, 
complete medium (500 µL, DMEM containing 10% fetal 
bovine serum and supplemented with 50 U/mL penicillin 
and 50 µg/mL streptomycin) was used. Immediately before 
the transfection, the number of living cell numbers for five 
different wells was calculated using trypan blue staining. 
The results demonstrated that there was approximately the 
same number of cells in each well. At the time of the transfec-
tion, the medium in each well was replaced with fresh com-
plete medium (500 µL). The CP-pDNA nanoparticles were 
added into each well and incubated with the cells for 6 days. 
The medium in each well was replaced by fresh medium at 
4 hours and 3 days after the transfection.   Transfection with 
Lipofectamine 2000 was performed according to the manual 
(Invitrogen). The standard calcium phosphate transfec-
tion was carried out with a kit purchased from Beyotime 
Biotechnology. Another transfection method in which the 
plasmid DNA was mixed with preformed needle-like calcium 
phosphate nanoparticles was tested according to a published 
report.35 All of the transfection experiments were performed 
with the same amount of plasmid (1 µg/well). The data are 
presented as the mean ± standard deviation (n = 5). The 
medium from the TGF-β1-transfected cell cultures was col-
lected at 3 days and 6 days after transfection. The medium 
TGF-β1 concentrations (n = 5 for each treatment) were tested 
with a rat TGF-β1 enzyme-linked immunosorbent assay kit 
(USCN Life Science and Technology, Missouri City, TX). 
The medium from the untreated mesenchymal stem cell 
cultures was used for blank controls.
Cytotoxicity assay
The mesenchymal stem cells were seeded in 96-well plates 
and incubated for 24 hours before transfection. For each 
well, 0.2 µg of plasmid DNA was transfected as CP-pDNA 
nanoparticles, with Lipofectamine 2000 or as naked plas-
mid DNA. Different weight ratios (2:1 to 10:1) of calcium 
phosphate:pDNA and Lipofectamine 2000:pDNA were 
tested. Four hours later, the medium was replaced by 
100 µL of fresh medium. After 3 days of incubation, the 
metabolic activities of the transfected cells were determined 
using a standard MTT (thiazolyl blue) assay. Moreover, the 
  cytotoxicity of calcium phosphate to mesenchymal stem cells 
was evaluated as well. Mesenchymal stem cells were exposed 
to calcium phosphate with 400 ng per well up to 6 days. After 
that, cell viability was tested by MTT assay.
Live cell imaging and confocal laser 
microscopy
To observe the processing of CP-pDNA nanoparticles 
in the cells, propidium iodide was used as the marker of 
plasmid DNA. Propidium iodide was added to the micro-
emulsions during the preparation of the nanoparticles. 
Time-lapse images of the cell morphology and movement 
were captured with a single 400 µm z-stack (15 mm slices) 
every 30 minutes for an 18-hour period. The pictures were 
taken under a Nikon TE 2000 PFS fluorescent microscope 
equipped with a motorized stage and an environmental 
sample chamber.
To investigate the mechanism of cellular uptake, cul-
ture medium containing 10 µg/mL colchicine was added 
when the CP-pDNA nanoparticles were transfecting the 
mesenchymal stem cells. After incubation for 4 hours, 
the transfection medium was replaced with serum-free 
DMEM medium with 10 µg/mL colchicine. Except for the 
addition of the colchicine, all of the transfection operation 
steps were the same. To observe nuclear transport, the 
mesenchymal stem cells transfected with propidium iodide-
labeled free plasmid DNA, propidium iodide-labeled 
CP-pDNA nanoparticles, and propidium iodide-labeled 
CP-pDNA nanoparticles plus colchicine (CP-pDNA 
nanoparticles + colchicine) were loaded onto poly-L-Lys-
coated slides, fixed with 4% formaldehyde (methanol-free, 
Polysciences Inc, Warrington, PA) in phosphate-buffered 
saline for 30 minutes and stained with Hoechst 33342 
(0.5 ng/mL) in saline for 10 minutes. The fixative was 
then removed, and the cells were washed with phosphate-
buffered saline to remove the formaldehyde. The slides 
were visualized with a confocal laser microscope (Zeiss 
LSM700, Gottingen, Germany) equipped with an inverted 
microscope (Axio Observer Z1, Zeiss) and four solid-state 
lasers (405, 473, 532, and 637 nm).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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statistical analysis
All of the values are represented as the mean ± standard 
deviation. The significant differences among different groups 
were tested using the Student’s t-test and a one-way analysis 
of variance with a least significant difference post hoc test 
by the SPSS statistic software (SPSS version 15.0, SPSS 
Inc, Chicago, IL). The difference between two groups was 
considered to be statistically significant at P , 0.01.
Results and discussion
Scheme 1A shows the process for preparation of the CP-
pDNA nanoparticle microemulsion. The resulting microemul-
sion was stirred for a further 10 minutes until completely 
translucent. This procedure was used to prevent particle 
nucleation and growth inhibition. Thereafter, the CP-pDNA 
nanoparticles were isolated from the microemulsion accord-
ing to a method modified from a published report,29 which 
used van der Waals chromatography via HPLC (vdW-HPLC 
laundering) to produce stable, nonagglomerated, concen-
trated particles (as shown in Scheme 1B). We introduced 
vdW-HPLC laundering to isolate CP-pDNA nanoparticles 
via regulation of the electrostatic surface charges with the 
mobile phase solvent to inhibit or promote surface charg-
ing with nonpolar solvents and polar solvents. Ultraviolet 
HPLC was employed to elute and detect the CP-pDNA 
nanoparticles to identify whether they had eluted com-
pletely. The c  hromatography of the CP-pDNA nanoparticle 
elution samples collected at different time points is shown in 
  Figure 1B. The clear peaks of the CP-pDNA nanoparticles 
were detected in those samples eluted at 4, 8, and 10 hours. 
No signal was found from the sample eluted at 12 hours, 
indicating that the CP-pDNA nanoparticles were completely 
eluted from the silica column in 12 hours. The narrow peaks 
also indicated the homogeneity and purity of the CP-pDNA 
nanoparticles. The peaks appeared at almost the same time 
(approximately 13 minutes) when the extraction solvent 
(ethanol/water,   volume ratio 70:30) with NaCl (5 × 10−4 M, 
prepared with CO2 free deionized water, pH 7) was being 
pumped at 0.5 mL/minute. Absolute ethanol, the nonpolar 
solvent, inhibits the surface charge to permit attractive van der 
Waals forces to dominate and achieve reversible particle depo-
sition onto the stationary phase. By maintaining this nonpolar 
environment, the weakly attracted organic molecules, such 
as plasmid DNA, Igepal CO-520, and cyclohexane, can be 
flushed through the column while the CP-pDNA nanopar-
ticles remain adhered. After the materials including free 
plasmid DNA, Igepal 520, and cyclohexane were virtually 
removed (the remaining amounts were below the detection 
limits of ultraviolet HPLC analysis), the washing solvent 
was shifted to a solution with more polarity, namely, ethanol/
water (v/v 70:30) with NaCl (5 × 10−4 M), which was prepared 
with CO2 free deionized water (pH 7.0). In this situation, the 
surface charge on both the stationary phase and the CP-pDNA 
nanoparticles possessed significant electrosteric repulsion 
Microemulsion
B
PO4
3−
/pDNA
CP-pDNA-NPs
microemulsion
Washing
solvent
Pump
Column
UV-detector
Fraction collector
Microemulsion
A
Magnetic stirrer
(Ca2+/pDNA)
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Scheme 1 (A) Process of preparing CP-pDNA nanoparticles by adding microemulsion B into microemulsion A at 20 drops per minute. (B) schematic setup of the 
high-pressure liquid chromatography system for isolation of CP-pDNA nanoparticles.
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to overcome the van der Waals attractive forces. During this 
process, the Cl− provided assistance for the CP-pDNA nano-
particles to release from the column and elute. Finally, the 
eluted CP-pDNA nanoparticle solution was concentrated to 
obtain a well dispersed CP-pDNA nanoparticle solution.
Panel a of Figure 1C displays the optimized plasmid DNA 
loading capacity of the calcium phosphate nanoparticles via 
agarose gel electrophoresis, in which different amounts of 
TGF-β1 DNA (from 0.1 to 10 µg) were used to prepare the 
CP-pDNA nanoparticle microemulsions, while the same 
amounts of calcium and phosphate ions (1 µg) were used for 
different preparations. From the results of the gel electropho-
resis (panel a of Figure 1C), we observed that 2:1 was the 
optimized weight ratio of calcium phosphate to plasmid DNA, 
indicating that the optimized loading capacity of plasmid 
DNA in the total CP-pDNA nanoparticles was approximately 
33% (w/w). This loading capacity is significantly higher 
than that of the lipid-coated nano-calcium phosphate lipid/
DNA weight ratio of 10:1 stated in one published report.36 
To confirm the integrity of the plasmid DNA incorporated 
into the nanoparticles, SmaI digestion of plasmid DNA 
released from the CP-pDNA nanoparticles was performed. 
Panel b of Figure 1C demonstrates the gel electrophoresis 
results of the TGF-β1 plasmid DNA cut into three fragments 
(approximately 4.5 kb, 2.5 kb, and 0.6 kb) by SmaI diges-
tion, ie, the plasmid DNA recovered from the CP-pDNA 
nanoparticles shows the same digestion pattern as that of 
free plasmid DNA. In addition, no smears were observed on 
the recovered plasmid DNA. Therefore, the plasmid DNA 
encapsulated in CP-pDNA nanoparticles was intact, which 
suggests that the integrity of the plasmid TGF-β1 in the CP-
pDNA nanoparticles was maintained. Panel c of Figure 1C 
reveals that plasmid DNA encapsulated into the calcium 
phosphate nanoparticle could still keep the supercoiled con-
formation. Moreover, calcium concentrations had no effect 
on the topological structure of plasmid DNA since there were 
no obvious changes observed in the intensity of fluorescence 
strips from different lines (panel c of Figure 1C).
TEM images were taken with a JEM-2100 instrument 
for CP-pDNA nanoparticles prepared with different weight 
ratios of calcium phosphate to plasmid DNA (0.1:1, 0.5:1, 
1:1, 2:1, 5:1, and 10:1; panels a–f of Figure 2A). There was no 
significant size variation between the different preparations, 
but when the calcium phosphate to plasmid DNA weight 
ratio increased to 10:1, the particle size distribution became 
extremely nonuniform. The CP-pDNA nanoparticles prepared 
at a 2:1 ratio were monodispersed, and their diameters were 
further characterized. The average diameter of the CP-pDNA 
nanoparticles was approximately 20–50 nm with a spherical 
shape (panel e of Figure 2A), based on the measurements of 
150 nanoparticles in the TEM   photomicrographs. The particle 
size distribution was measured at a calcium phosphate to 
plasmid DNA weight ratio of 2:1, demonstrating that the CP-
pDNA nanoparticle diameters ranged from 25 nm to 50 nm 
(Figure 2B), which was consistent with the findings of TEM 
(panel e of   Figure 2A). The CP-pDNA nanoparticles with 
this small and uniform particle size, which was comparable 
with or even smaller than that of previous studies,25,31 were 
well dispersed without any sign of   agglomeration. Small 
size and effective dispersion contribute greatly to transfec-
tion efficiency.
Mesenchymal stem cells have been widely investigated 
for use in gene therapies.33 In this study, we isolated mesen-
chymal stem cells from the tibia and the femur of one-day-old 
male white Sprague-Dawley rats. Passage 3 rat mesenchymal 
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Figure 2 (A) Transmission electron microscopy images. Panels a–f show CP-pDNA 
nanoparticles made with calcium phosphate/plasmid DNA ratios equal to 0.1:1 (a), 
0.5:1 (b), 1:1 (c), 2:1 (d), 5:1 (e), and 10:1 (f); panel g shows needle-like calcium 
phosphate particles. Panels h and i show the standard calcium phosphate transfection 
agent. Panel h shows quiescence at 0.5 hours; panel i shows quiescence at 8 hours. 
(B)  Particle  size  distribution  of  CP-pDNA  nanoparticles  made  with  a  calcium 
phosphate/plasmid DNA ratio of 2:1.
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stem cells appeared fibroblastic and   homogeneous in size 
and morphology before transfection, as shown in   Figure 3A. 
Figure 3B shows the fibroblastic appearance of the stem 
cells after transfection. Immunofluorescence staining 
showed that the rat mesenchymal stem cells were positive 
for CD13, CD44, CD106, and vimentin, as revealed by red 
fluorescence (Figure 3C), and negative for CD34 and CD71 
(data not shown). For immunofluorescence analysis, rabbit 
antimouse antibodies, CD13, CD44, CD106, CD34, CD71, 
and vimentin, were used as the primary antibodies, and 
Cy3-conjugated sheep antirabbit IgG was employed as the 
secondary antibody. CY3 is a type of biological fluorescent 
dye, which is activated by laser light at the wavelength of 
554 nm and emits fresh red fluorescence within the wave-
length range of 568–574 nm. Thus, Cy3-conjugated sheep 
antirabbit IgG combined with the primary antibodies (rabbit 
antimouse antibodies CD13, CD44, CD106, and vimentin) 
showed red fluorescence (Figure 3C), indicating the presence 
of the surface markers, CD13, CD44, CD106, and vimentin, 
respectively. However, no fluorescence was observed in the 
CD34 and CD71 groups. This indicates that the mesenchy-
mal lineage surface markers were present in the cultures and 
that hematopoietic cell markers were not. Therefore, based 
on morphology and surface markers, the cultured cells were 
probably mesenchymal stem cells.33,37 Furthermore, the same 
results were obtained after transfection, indicating that the 
stem cells had not differentiated following transfection.
Plasmid TGF-β1 was used as an exogenous gene to trans-
fect the mesenchymal stem cells. TGF-β1 is a member of a 
large family of structurally related peptides that plays a key 
role in regulating cell proliferation, differentiation, apoptosis, 
and production of extracellular matrix.38 It has been reported 
that TGF-β1 is an effective stimulator of chondrogenesis 
in mesenchymal stem cells.39 Thus, the overexpression of 
TGF-β1 in mesenchymal stem cells could be used in carti-
lage tissue regeneration. We believe that with development 
in research, the expression of TGF-β1 could be used in other 
types of tissue regeneration.
Herein, mesenchymal stem cells were used in gene trans-
fection experiments. The optimized phosphate/pDNA ratio 
during CP-pDNA nanoparticle preparation, which displayed 
highest transfection efficiency for mesenchymal stem cells 
in vitro at day 3 and day 6, was 2:1 (Figure 4A). There was 
an approximately 18-fold elevation in TGF-β1 expression 
in the mesenchymal stem cells treated with   CP-pDNA 
nanoparticles prepared at a 2:1 ratio compared with those 
from the control groups treated with plasmid only. In all 
of the subsequent studies, CP-pDNA nanoparticles were 
prepared at a 2:1 ratio. The most suitable dose of CP-pDNA 
nanoparticles for transfection was 1 µg, as demonstrated in 
the dose-response assay (Figure 4B).
For comparison with our CP-pDNA nanoparticles, 
the transfection efficiencies of a standard Lipofectamine 
2000 method, a standard calcium phosphate transfection 
method, and a method in which plasmid DNA was mixed 
with preformed needle-like calcium phosphate nanoparticles 
were tested. According to the method reported by Lai et al,40 
in which the resulting particle was approximately 4–8 nm 
in diameter and approximately 80–100 nm in length, we 
also prepared needle-like calcium phosphate nanoparticles 
approximately 10–20 nm in diameter and approximately 
100–120 nm in length (panel g of Figure 2A. As shown 
in Figure 4C, there was no significant difference between 
the TGF-β1 expression levels of the mesenchymal stem 
cells transfected with our CP-pDNA nanoparticles and 
the same amount of plasmid mediated by Lipofectamine 
2000. As expected, the transfection efficiency of our CP-
pDNA nanoparticles was significantly higher than those 
A
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Figure 3 (A) Mesenchymal stem cells before transfection. (B) Mesenchymal stem 
cells after transfection. (C) surface markers used to identify mesenchymal stem 
cells; CD13, CD44, CD106, and vimentin were all positive, as revealed by red 
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of the standard calcium phosphate transfection (P , 0.01, 
Student’s t-test) and the needle-like calcium phosphate 
nanoparticles (P , 0.01, Student’s t-test). Although the CP-
pDNA nanoparticles demonstrated transfection efficiency 
comparable with that of Lipofectamine 2000, as shown in 
Figure 4C, the lower cytotoxicity reveals the superior results 
using   CP-pDNA nanoparticles (Figure 5A). The CP-pDNA 
nanoparticles prepared in this study showed other excellent 
advantages, such as ultralow particle size (approximately 
20–50 nm), spherical shape, effective dispersion, and 
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  maintenance of the integrity of the plasmid encapsulated in 
the calcium phosphate nanocomposite particles. Effective 
dispersion is prerequisite for the ultralow size and large con-
tact surface which result in enhanced cellular uptake. Aside 
from particle size, particle morphology also greatly affects 
gene   transfection.35 However, needle-like calcium phos-
phate particles, unlike spherical CP-pDNA nanoparticles, 
are relatively difficult for cells to take up.41,42 This difficulty 
may possibly be because the shape of needle-like calcium 
phosphate particles is unfavorable for endocytosis. A more 
exact explanation will be addressed in our future work. In the 
case of standard calcium phosphate, agglomeration caused 
lower transfection efficiency because severe agglomeration 
was observed after 8 hours of static placing (panels h and i of 
Figure 2A). More importantly, these CP-pDNA nanoparticles 
have the capacity to keep encapsulated DNA intact during 
the entire process of CP-pDNA nanoparticle production, 
including the use of solvents such as cyclohexane and Igepal 
CO-520, and isolation through vdW-HPLC laundering and 
dialysis, which is another basic requirement leading to high 
transfection efficiency. All of these factors greatly affect 
the process of cellular uptake and increase the transfection 
efficiency. Additionally, plasmid TGF-β1 at the concentra-
tion used in this study (200 ng/well) was nontoxic to mesen-
chymal stem cells, as shown in Figure 5B. Furthermore, the 
toxicity of calcium phosphate to mesenchymal stem cells was 
also investigated during chronic exposure for up to 6 days, 
and the results show that calcium phosphate was not toxic to 
mesenchymal stem cells, as shown in Figure 5C.
Live cell imaging was used to investigate the transpor-
tation process of CP-pDNA nanoparticles in mesenchymal 
stem cells. Propidium iodide was used as a marker for plas-
mid DNA. The propidium iodide molecules were bound to 
plasmid DNA and incorporated into the nanoparticles dur-
ing preparation. The cells in which foreign plasmid DNA 
had accumulated could be detected as red fluorescence. 
The CP-pDNA/propidium iodide nanoparticle-transfected 
mesenchymal stem cells were continuously observed under 
a live cell image system for 18 hours. Representative images 
at 0, 4, 8, and 18 hours after transfection are shown in the 
middle panels of Figure 6. Generally, red fluorescence was 
detected in a few cells by 4 hours after transfection. At the 
beginning (0 hours), no red fluorescence was observed in 
any of the tested groups (Figure 6). However, over time, red 
fluorescence spots increasingly appeared in the CP-pDNA 
nanoparticle group, and images were taken in the same field 
of view. That is, images in the same group were pictures of 
the same cells taken at different time points. The number of 
cells turning red gradually increased until 18 hours. In the 
absence of calcium phosphate, free DNA plasmids could not 
enter the mesenchymal stem cells (upper panels in Figure 6). 
The same situation occurred with mesenchymal stem cells 
transfected with CP-pDNA nanoparticles/propidium iodide 
added with colchicine (lower panels in Figure 6). Colchicine 
is a widely used endocytosis inhibitor43,44 that can effectively 
inhibit endocytosis in a cell membrane, as shown by the 
significantly reduced red fluorescence observed in the lower 
  panels of Figure 6. The increasing intensive red   fluorescence 
in the CP-pDNA nanoparticle group indicated that an 
increasing amount of plasmid DNA was transported into 
the cytoplasm. A previous study has confirmed that calcium 
phosphate is taken up by endocytosis, dissolved in acidic 
compartments (for example, endosomes and lysosomes), 
and subsequently released into the cytoplasm.45 The results 
illustrated by the lower panels of Figure 6 also confirm that 
CP-pDNA nanoparticles were transported by the cell endo-
cytosis pathway. Once propidium iodide was released into 
cytoplasm, it could combine with the large amount of DNA 
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originally existing inside the mesenchymal stem cells, and 
thus markedly red fluorescence was observed, as shown in 
the group of mesenchymal stem cells transfected with CP-
pDNA nanoparticles/propidium iodide (middle panels of 
Figure 6).
Laser confocal fluorescence microscopy was used to 
track the subcellular positions of CP-pDNA nanoparticles/ 
propidium iodide. Hoechst 33342 was used to show the 
  positions of the nuclei, and propidium iodide was used to 
track the plasmid DNA. Figure 7A shows the CP-pDNA 
nanoparticle transportation process in the mesenchymal 
stem cells at 0, 8, 12, and 18 hours after transfection. After 
12 hours of transfection, plasmid DNA was clearly observed 
in the cytoplasm, and at 18 hours, plasmid DNA was clearly 
observed in the nuclei, demonstrating that CP-pDNA 
nanoparticles could successfully deliver foreign DNA into 
mesenchymal stem cell nuclei to ensure expression of thera-
peutic nucleic acids. The CP-pDNA nanoparticles entered the 
cell by endocytosis. To prevent degradation, the CP-pDNA 
nanoparticles should escape the endosome before its fusion 
with lysosomes. The low pH established in the lysosomes 
leads to dissolution of calcium phosphate and release of 
DNA. Nevertheless, Maitra46 found that partial dissolution of 
calcium phosphate can destabilize the lysosomal membrane 
and facilitate release of the remaining nanoparticles and plas-
mid DNA into the cytoplasm. Thereafter, the plasmid DNA 
will move toward the nucleus.47 It is still unknown whether 
CP-pDNA nanoparticles penetrate the nuclear membrane or 
enter the nucleus during mitosis or other cell cycle periods. 
Further investigation concerning the mechanism of cellular 
uptake will be conducted in our future work.
The mesenchymal stem cells transfected with CP-pDNA/
propidium iodide nanoparticles were compared with those 
achieved using other methods (for example, needle-like cal-
cium phosphate nanoparticles, a standard calcium phosphate 
transfection kit, and Lipofectamine 2000). At 18 hours after 
transfection, plasmid DNA were abundantly distributed in 
mesenchymal stem cells transfected with CP-pDNA nano-
particles or Lipofectamine 2000 methods, while much less 
was observed in those transfected with needle-like calcium 
phosphate nanoparticles or the standard calcium phosphate 
transfection kit (panels a, b, c, and f in Figure 7B). Plasmid 
DNA could be clearly observed in the nuclei of mesenchymal 
stem cells transfected with the CP-pDNA nanoparticles and 
Lipofectamine 2000 (panels c and f in Figure 7B, shown using 
arrows). Notably, it seems that the CP-pDNA nanoparticle 
method provides more rapid transportation of plasmid DNA 
than does Lipofectamine 2000. Eight hours after CP-pDNA 
nanoparticle   transfection, approximately the same plasmid 
DNA abundance was seen in the mesenchymal stem cells as 
seen 18 hours after Lipofectamine 2000-mediated transfec-
tion (panels e and c in Figure 7B). This result indicates that 
TGF-β1 transfected by CP-pDNA nanoparticles might take 
less time to reach a sufficient expression level.
Conclusion
The CP-pDNA nanoparticles that have been constructed in this 
study had such advantages as ultralow particle size (20 nm) 
and excellent dispersity, in addition to an ability to keep 
encapsulated DNA intact. The TGF-β1 plasmid was success-
fully encapsulated into calcium phosphate   nanoparticles with 
a relatively large loading capacity (the weight ratio of plasmid 
DNA in the total CP-pDNA nanoparticles was approximately 
33%). Interestingly, the SmaI digestion assay revealed 
that the plasmid TGF-β1 in the CP-pDNA nanoparticles 
was intact after all of these production processes. The results 
of immunofluorescence staining showed the presence of mes-
enchymal lineage cell surface markers, CD13, CD44, CD106, 
and vimentin, and the absence of hematopoietic m  arkers, 
CD34 and CD71, indicating that the cells cultured were 
likely mesenchymal stem cells. After transfection, the stem 
cells had not differentiated. Compared with   Lipofectamine 
2000-mediated transfection, the cytotoxicity of CP-pDNA 
nanoparticles was significantly lower when the CP-pDNA 
nanoparticles or Lipofectamine 2000 to plasmid DNA weight 
ratios increased to 5:1, 8:1, or 10:1, which demonstrated that 
the CP-pDNA nanoparticles were safe as gene vectors. Both 
plasmid TGF-β1 and calcium phosphate were not toxic to the 
mesenchymal stem cells. Most importantly, the transfection 
efficiency of the CP-pDNA nanoparticles was comparable with 
that of   Lipofectamine 2000, but it was significantly higher than 
that of standard calcium phosphate transfection (P , 0.01, 
Student’s t-test) and use of needle-like calcium phosphate 
nanoparticles (P , 0.01, Student’s t-test). This study represents 
considerable progress in the use of calcium phosphate particles 
as nonviral gene vectors. In general, CP-pDNA nanoparticles 
appear to be a promising candidate as a nonviral gene vector 
in gene therapy and tissue engineering.
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